NCT06224309Recruiting
Preliminary Assessment of [18F]BL40 in PET/CT Scans
A Phase 2 Study to Evaluate the in Vivo Biodistribution, Radiation Dosimetry and a Preliminary Assessment of the Diagnostic Performance of [18F]BL40
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor function. There is a need for novel tracers to image CXCR4-expressing tumors for better detection, staging, and monitoring of aggressive cancers without the need for invasive biopsy procedures that may not always properly capture the extent of a patient's disease. This study looks to assess the safety and efficacy of a novel radiopharmaceutical known as 18F-BL40 through its use in a PET/CT scan. Participants will receive 2 PET/CT scans: 18F-BL40 and 18F-FDG as part of this study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 27 Dec 2023
- Start date
- 10 Jun 2024
- Primary completion date
- 15 Mar 2027
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Diffuse large B-cell lymphoma, Mantle cell lymphoma, Chronic lymphocytic leukaemia, Multiple myeloma
- NCT number
- NCT06224309
What you commit to
- Study type: Observational
- Planned participants: 30
- From 10 Jun 2024 to the primary completion date, 15 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Medically unstable (e.g., acute illness, unstable vital signs)
- Participants with a history of uncontrolled allergic reactions and/or known or expected hypersensitivity to the peptide diagnostic \[18F\]BL40 or any of its excipients.
Other
- Pregnant or breast-feeding
- Unable to lie supine for the duration of imaging
- Unable to provide written consent
- Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm)
Who the study is looking for
- Age ≥19 years
- Life expectancy ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Participants with newly diagnosed or documented recurrent malignancy with one of the following cancers:
- Diffuse large B-Cell lymphoma
- Multiple myeloma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Chronic lymphocytic leukemia/small cell lymphoma
- Waldenström Macroglobulinemia
Age in the registry: 19 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| BC Cancer Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.